FluoGuide A/S Stock price

Equities

FLUO

DK0061123312

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm 06:30:41 2024-03-28 am EDT 5-day change 1st Jan Change
48.2 SEK -0.21% Intraday chart for FluoGuide A/S -4.37% -21.24%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 382M 55.38M 589M
Net income 2024 * -42M -6.08M -64.73M Net income 2025 * -83M -12.02M -128M EV / Sales 2024 * -
Net cash position 2024 * 256M 37.02M 394M Net cash position 2025 * 173M 25.06M 267M EV / Sales 2025 * -
P/E ratio 2024 *
-13.1 x
P/E ratio 2025 *
-6.67 x
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 58.63%
More Fundamentals * Assessed data
Dynamic Chart
FluoGuide A/S Approves Board Changes CI
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001 CI
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer CI
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference CI
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague CI
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer CI
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer CI
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer CI
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors CI
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day-0.21%
1 week-4.37%
Current month-12.04%
1 month-11.07%
3 months-23.49%
6 months-42.62%
Current year-21.24%
More quotes
1 week
47.80
Extreme 47.8
50.80
1 month
46.30
Extreme 46.3
61.60
Current year
46.30
Extreme 46.3
80.00
1 year
46.30
Extreme 46.3
101.00
3 years
35.50
Extreme 35.5
139.00
5 years
4.10
Extreme 4.1
160.00
10 years
4.10
Extreme 4.1
160.00
More quotes
Managers TitleAgeSince
Founder 61 18-01-29
Chief Executive Officer 60 17-12-31
Director of Finance/CFO 59 23-02-01
Members of the board TitleAgeSince
Director/Board Member 63 18-12-31
Director/Board Member - 22-12-31
Director/Board Member 53 20-12-31
More insiders
Date Price Change Volume
24-03-28 48.2 -0.21% 1 328
24-03-27 48.3 -1.02% 5,534
24-03-26 48.8 -2.40% 4,022
24-03-25 50 +0.20% 1,369
24-03-22 49.9 -0.99% 6,642

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 04:48 am EDT

More quotes
FluoGuide A/S is a Denmark-based biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent. The Company is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Company's main product, FG001, is designed using FluoGuide's uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock FluoGuide A/S - Nasdaq Stockholm